Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA ...
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.
UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...
Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.
The U.S. FDA’s complete response letter (CRL) for Biohaven Ltd.’s lead asset, troriluzole, to treat spinocerebellar ataxia has prompted a wave of downstream changes at the company. There will be a ...
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
Correspondence to Dr Thiago Junqueira Ribeiro Rezende, Department of Neurology, University of Campinas (UNICAMP), Campinas, SP, Brazil; thiago.jrezende{at}gmail.com Background Spinal cord damage is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback